Status In progress
Process STA
ID number 523
Referral date July 2012
Topic area
  • Cancer

Provisional Schedule

Closing date for invited submissions / evidence submission: 28 March 2013
1st appraisal committee meeting: 09 July 2013
2nd appraisal committee meeting 04 September 2013

Project Team

Project lead Liv Gualda

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
08 February 2017 Committee meeting: 3
01 September 2016 The appraisal ‘Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel) [ID523]’ is currently suspended. Roche have advised that they are in ongoing discussions with NHS England to seek agreement of a commercial scheme that can be considered by NICE. All three parties (NHS England, NICE and Roche) are committed to securing the earliest possible date for the NICE committee to re-consider this appraisal. Current timelines suggest a NICE Committee meeting would be scheduled in early 2017. More information on anticipated timelines will be communicated as it becomes available.
11 June 2014

Please note that the NICE Decision Support Unit (DSU) are undertaking a discussion paper for assessing technologies that are not cost effective at a zero price.

The NICE Guidance Executive team will consider the outcome of the DSU’s explanations before considering the next steps for pertuzumab in combination with trastuzumab and docetaxel for treating HER2-positive metastatic or locally recurrent unresectable breast cancer [ID523].

14 October 2013

Please note that there has been a delay for the release of the Final Appraisal Determination (FAD) for this appraisal. Noting the manufacturer’s comment that it is not possible to set a price at which pertuzumab would meet current acceptability criteria for cost effectiveness, the Institute’s Guidance Executive has asked the technology appraisals team to explore this further with a view to resolving the issue.

We will update this webpage with further information once we have considered the options for proceeding with this additional work.


For further information on how we develop guidance, please see our page about NICE technology appraisal guidance